OPC-14523

DB05422ExperimentalSmall molecule

OPC-14523 is an antidepressant drug developed by Otsuka America Pharmaceutical.

Mechanism: OPC-14523 is a serotonin reuptake inhibitor. It treats depression, especially refractory depression, in a mammal, including a human, by administering to the mammal a sigma receptor ligand in combination with an antidepressant agent. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a sigma receptor ligand and a serotonin reuptake inhibitor.
Curator reviewed
Primary indication: Investigated for use/treatment in bulimia, depression, and obsessive-compulsive disorders.Curator reviewed
Formula / weight: C₂₃H₂₈ClN₃O₂ · 413.95 g/mol (avg)
Code names: OPC-14523

Resolves to

Compound

Structure

InChIKeyTZZGTNZBLPCBIS-UHFFFAOYSA-NSMILESCOC1=CC=CC2=C1CCC(=O)N2CCCN1CCN(CC1)C1=CC=CC(Cl)=C1

Targets

What you can answer from here — as of August 30, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with OPC-14523, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.